Stocktoria
Jyong Biotech Ltd. MENS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2025-06-17
Chart by TradingView
3/9
Piotroski F — financial health
-13.42
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| Financials | ||
| Operating income | -$2.6M | -$2.1M |
| Net income | -$4.7M | -$3.0M |
| Operating cash flow | -$3.0M | -$3.6M |
| Total assets | $20.8M | $6.4M |
| Total liabilities | $45.7M | $42.9M |
| Shareholders' equity | -$24.9M | -$36.5M |
| Ratios | ||
| Return on assets | -22.5% | -47.4% |
| Return on equity | 18.8% | 8.3% |
| Debt / equity | -0.09× | — |
| Current ratio | 0.45 | 0.02 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -13.42 (distress)
- Working capital / assets -0.927
- Retained earnings / assets -1.817
- EBIT / assets -0.125
- Equity / liabilities -0.545
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001954488 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.